scispace - formally typeset
Open AccessJournal ArticleDOI

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

TLDR
Authors/Task Force Members (François Macha, Colin Baigentb,∗∗,2, Alberico L. Catapanoc), ESC Committee for Practice Guidelines (CPG) (Stephan Windeckeraa), ESC National Cardiac Societies (Djamaleddine Nibouchean, Parounak H. Patelcl)
About
This article is published in Atherosclerosis.The article was published on 2019-09-02 and is currently open access. It has received 2972 citations till now. The article focuses on the topics: Lipid modification & Very low-density lipoprotein.

read more

Citations
More filters
Journal ArticleDOI

Statins and All‐Cause Mortality in Patients Undergoing Hemodialysis

TL;DR: The results showed that in adult patients undergoing maintenance hemodialysis, statin therapy, preferably combined with ezetimibe, was associated with a lower risk of all‐cause mortality.
Journal ArticleDOI

Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review

TL;DR: The current state of evidence on lipid management in patients presenting with ACS is detailed, directions for identification of patients who may benefit from early escalation of lipid‐lowering therapy are provided, and a treatment algorithm aimed at attaining guideline‐recommended low‐density lipoprotein cholesterol levels is proposed.
Journal ArticleDOI

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction.

TL;DR: As first of its class to be approved, icosapent ethyl offers a new option to further reduce cardiovascular risks in patients already treated with maximally tolerated statins.
Journal ArticleDOI

Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets : Lipid-lowering combination therapy.

TL;DR: New RCT, meta-analysis, and Mendelian randomization data, support that the main determinant of risk reduction is the absolute LDL reduction regardless of LLT, and the "high-intensity statin therapy” concept should be substituted by “high- intensity lipid lowering therapy.”
References
More filters
Journal ArticleDOI

Atherosclerosis — An Inflammatory Disease

TL;DR: Atherosclerosis is an inflammatory disease as discussed by the authors, and it is a major cause of death in the United States, Europe, and much of Asia, despite changes in lifestyle and use of new pharmacologic approaches to lower plasma cholesterol concentrations.
Journal ArticleDOI

2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Giuseppe Mancia, +89 more
TL;DR: In this article, a randomized controlled trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly people was presented. But the authors did not discuss the effect of the combination therapy in patients living with systolic hypertension.
Journal Article

Atherosclerosis is an Inflammatory Disease

TL;DR: Despite changes in lifestyle and the use of new pharmacologic approaches to lower plasma cholesterol concentrations, cardiovascular disease continues to be the principal cause of death in the United States, Europe, and much of Asia.

Standards of Medical Care in Diabetes

TL;DR: These standards of care are intended to provide clinicians, patients, researchers, payors, and other interested individuals with the components of diabetes care, treatment goals, and tools to evaluate the quality of care.
Related Papers (5)

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

François Mach, +120 more